MS Views and News – a Patient Advocacy Organization that provides educational information for ALL affected by Multiple Sclerosis

Being Empowered with MS information IS beneficial. We Believe YOU (the MS Patients and Caregivers) should Be Empowered with Multiple Sclerosis information.

Visit our archived MS educational program video- recordings. Visit www.youtube.com/msviewsandnews

Visit our website: MS Views and News.org

joomla ecommerce template

Scroll to Review all the resources found on the left side of this blog site. Use our 'search by topic' tool, when wanting to find specific information

.

Disclaimer:

'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

==================================

Thursday, October 18, 2012

FDA extends review of Biogen's multiple sclerosis drug



(Reuters) - Biotechnology company Biogen Idec Inc said U.S. health regulators extended by three months the review date of its much-awaited multiple sclerosis (MS) drug BG-12, but analysts said the delay was only a minor setback.
Shares of Biogen were down 2 percent at $150.72 in morning trading on the Nasdaq.
The stock has risen more than 50 percent over the past 12 months, largely on optimism about BG-12, which showed robust results in trials and had no safety concerns.
Analysts said the delay would push the review date to March, but added such extensions were not uncommon.
"The registrational studies for BG-12 - DEFINE and CONFIRM - enrolled about 1,200 and 1,400 patients, respectively. Given the size and complexity of the filings, we are not surprised that the FDA would require additional time to review the application," Barclays Capital analyst Anthony Butler said.
The U.S. Food and Drug Administration said it needed additional time to review the application, but did not ask for additional studies, according to Biogen.

..


If you would like, you can comment to our blog posts
 LIKE this Blog by clicking the LIKE button - top left
 REMAIN up to date with MS News and Education
Visit: www.msviewsandnews.org  to register
.

1 comment:

Mistylilacs04 said...

I am so sick of taking a shot every day and can't wait for BG-12 to be available. Another delay does not brighten my day! I know it's important for the FDA to check and re-check all our drugs but could they check a little faster!!!